Staphylococcal vaccines are prophylactic agents developed to prevent infections caused by Staphylococcus aureus, a pathogenic bacterium that frequently colonizes human skin and mucous membranes, often targeting surface proteins or toxins for immune response induction.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
Two or more vaccines in a single dosage form.
Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.

Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. (1/79)

Vaccines based on preferential expression of bacterial antigens during human infection have not been described. Staphylococcus aureus synthesized poly-N-succinyl beta-1-6 glucosamine (PNSG) as a surface polysaccharide during human and animal infection, but few strains expressed PNSG in vitro. All S. aureus strains examined carried genes for PNSG synthesis. Immunization protected mice against kidney infections and death from strains that produced little PNSG in vitro. Nonimmune infected animals made antibody to PNSG, but serial in vitro cultures of kidney isolates yielded mostly cells that did not produce PNSG. PNSG is a candidate for use in a vaccine to protect against S. aureus infection.  (+info)

Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. (2/79)

BACKGROUND: In patients with decreased resistance to infection, Staphylococcus aureus is a major cause of bacteremia and its complications. The capsular polysaccharides are essential for the pathogenesis of and immunity to S. aureus infection and are targets for vaccines. METHODS: In a double-blind trial involving patients with end-stage renal disease who were receiving hemodialysis, we evaluated the safety, immunogenicity, and efficacy of a vaccine with S. aureus type 5 and 8 capsular polysaccharides conjugated to nontoxic recombinant Pseudomonas aeruginosa exotoxin A. Between April 1998 and August 1999, 1804 adult patients at 73 hemodialysis centers were randomly assigned to receive a single intramuscular injection of either vaccine or saline. IgG antibodies to S. aureus type 5 and 8 capsular polysaccharides were measured for up to two years, and episodes of S. aureus bacteremia were recorded. Efficacy was estimated by comparing the incidence of S. aureus bacteremia in the patients who received the vaccine with the incidence in the control patients. RESULTS: Reactions to the vaccine were generally mild to moderate, and most resolved within two days. The capsular polysaccharides elicited an antibody response of at least 80 microg per milliliter (the estimated minimal level conferring protection) in 80 percent of patients for type 5 and in 75 percent of patients for type 8. The efficacy during weeks 3 to 54 was only 26 percent (P=0.23). However, between weeks 3 and 40 after vaccination, S. aureus bacteremia developed in 11 of 892 patients in the vaccine group who could be evaluated for bacteremia, as compared with 26 of 906 patients in the control group (estimate of efficacy, 57 percent; 95 percent confidence interval, 10 to 81 percent; nominal P=0.02). CONCLUSIONS: In patients receiving hemodialysis, a conjugate vaccine can confer partial immunity against S. aureus bacteremia for approximately 40 weeks, after which protection wanes as antibody levels decrease.  (+info)

Structural basis for abrogated binding between staphylococcal enterotoxin A superantigen vaccine and MHC-IIalpha. (3/79)

Staphylococcal enterotoxins (SEs) are superantigenic protein toxins responsible for a number of life-threatening diseases. The X-ray structure of a staphylococcal enterotoxin A (SEA) triple-mutant (L48R, D70R, and Y92A) vaccine reveals a cascade of structural rearrangements located in three loop regions essential for binding the alpha subunit of major histocompatibility complex class II (MHC-II) molecules. A comparison of hypothetical model complexes between SEA and the SEA triple mutant with MHC-II HLA-DR1 clearly shows disruption of key ionic and hydrophobic interactions necessary for forming the complex. Extensive dislocation of the disulfide loop in particular interferes with MHC-IIalpha binding. The triple-mutant structure provides new insights into the loss of superantigenicity and toxicity of an engineered superantigen and provides a basis for further design of enterotoxin vaccines.  (+info)

Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon. (4/79)

A candidate vaccine against staphylococcal enterotoxin B (SEB) was developed using a Venezuelan equine encephalitis (VEE) virus vector. This vaccine is composed of a self-replicating RNA, termed "replicon," containing the VEE nonstructural genes and cis-acting elements and a gene encoding mutagenized SEB (mSEB). Cotransfection of baby hamster kidney cells with the mSEB replicon and 2 helper RNA molecules resulted in the release of propagation-deficient mSEB-VEE replicon particles (mSEB-VRPs). Mice inoculated subcutaneously with mSEB-VRPs were protected (15 of 20 mice) from a challenge with 5 median lethal dose units of wild-type (wt) SEB. T cells from mice vaccinated with mSEB-VRP responded normally both in vitro to wt SEB and in recall response to the inactivated mSEB polypeptide. The profile of cytokines measured after challenge with wt SEB suggested that the mode of protection was predominantly Th1 dependent. Our results suggest that the VEE replicon is a practical and convenient model system for evaluating efficacy of vaccines for the control of bacterial diseases.  (+info)

Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. (5/79)

For the design of potent subunit vaccines, it is of paramount importance to identify all antigens immunologically recognized by a patient population infected with a pathogen. We have developed a rapid and efficient procedure to identify such commonly recognized antigens, and here we provide a comprehensive in vivo antigenic profile of Staphylococcus aureus, an important human pathogen. S. aureus peptides were displayed on the surface of Escherichia coli via fusion to one of two outer membrane proteins (LamB and FhuA) and probed with sera selected for high Ab titer and opsonic activity. A total of 60 antigenic proteins were identified, most of which are located or predicted to be located on the surface of the bacterium or secreted. The identification of these antigens and their reactivity with individual sera from patients and healthy individuals greatly facilitate the selection of promising vaccine candidates for further evaluation. This approach, which makes use of whole genome sequence information, has the potential to greatly accelerate and facilitate the formulation of novel vaccines and is applicable to any pathogen that induces Abs in humans and/or experimental animals.  (+info)

Functional selection of vaccine candidate peptides from Staphylococcus aureus whole-genome expression libraries in vitro. (6/79)

An in vitro protein selection method, ribosome display, has been applied to comprehensively identify and map the immunologically relevant proteins of the human pathogen Staphylococcus aureus. A library built up from genomic fragments of the virulent S. aureus COL strain (methicillin-resistant S. aureus) allowed us to screen all possible encoded peptides for immunoreactivity. As selective agents, human sera exhibiting a high antibody titer and opsonic activity against S. aureus were used, since these antibodies indicate the in vivo expression and immunoreactivity of the corresponding proteins. Identified clones cluster in distinct regions of 75 genes, most of them classifiable as secreted or surface-localized proteins, including previously identified virulence factors. In addition, 14 putative novel short open reading frames were identified and their immunoreactivity and in vivo mRNA expression were confirmed, underscoring the annotation-independent, true genomic nature of our approach. Evidence is provided that a large fraction of the identified peptides cannot be expressed in an in vivo-based surface display system. Thus, in vitro protein selection, not biased by the context of living entities, allows screening of genomic expression libraries with a large number of different ligands simultaneously. It is a powerful approach for fingerprinting the repertoire of immune reactive proteins serving as target candidates for active and passive vaccination against pathogens.  (+info)

RUNT DISEASE INDUCED IN NEONATAL MICE BY STERILE BACTERIAL VACCINES. (7/79)

A form of runt disease has been produced in neonatal CF-1 and ICR mice by the repeated injection of 10(9) washed, autoclaved, saline-suspended staphylococci or streptococci. The most severely affected animals showed a marked decrease in lymphoid tissues and resembled grossly and microscopically animals suffering from the classical runt or wasting disease described by others. The timing of the initial antigenic stimulation was of importance, and animals started on their course of injections at an age of 48 hours or older showed no effect. There was a considerable variation in the severity of the disease within litters and from one litter to another. This variation could not be ascribed to a difference in susceptibility between sexes, since both male and female mice were observed to runt under appropriate conditions. Germ-free ICR mice were much more resistant to the runting phenomenon than conventional animals of the same strain, but could be induced to runt by injection of the staphylococcal vaccine suspended in homologous antiserum. The relationship of the runting phenomenon described here and classical runt disease or runting by adrenal hormones is discussed.  (+info)

Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine. (8/79)

Staphylococcus aureus and Staphylococcus epidermidis both synthesize the surface polysaccharide poly-N-acetyl-beta-(1-6)-glucosamine (PNAG), which is produced in vitro with a high level (>90%) of the amino groups substituted by acetate. Here, we examined the role of the acetate substituents of PNAG in generating opsonic and protective antibodies. PNAG and a deacetylated form of the antigen (dPNAG; 15% acetylation) were conjugated to the carrier protein diphtheria toxoid (DT) and used to immunize animals. Mice responded in a dose-dependent fashion to both conjugate vaccines, with maximum antibody titers observed at the highest dose and 4 weeks after the last of three weekly immunizations. PNAG-DT and dPNAG-DT vaccines were also very immunogenic in rabbits. Antibodies raised to the conjugate vaccines in rabbits mediated the opsonic killing of various staphylococcal strains, but the specificity of the opsonic killing was primarily to dPNAG, as this antigen inhibited the killing of S. aureus strains by both PNAG- and dPNAG-specific antibodies. Passive immunization of mice with anti-dPNAG-DT rabbit sera showed significant levels of clearance of S. aureus from the blood (54 to 91%) compared to control mice immunized with normal rabbit sera, whereas PNAG-specific antibodies were ineffective at clearing S. aureus. Passive immunization of mice with a goat antiserum raised to the dPNAG-DT vaccine protected against a lethal dose of three different S. aureus strains. Overall, these data show that immunization of animals with a conjugate vaccine of dPNAG elicit antibodies that mediated opsonic killing and protected against S. aureus infection, including capsular polysaccharide types 5 and 8 and an untypable strain.  (+info)

Staphylococcal vaccines are immunizations that are developed to protect against infections caused by the Staphylococcus bacteria, particularly Staphylococcus aureus. These vaccines typically contain components of the bacterial cell wall or toxins that stimulate an immune response in the body, leading to the production of antibodies that can recognize and neutralize the bacteria if they invade the body in the future.

There are currently no licensed staphylococcal vaccines available for use in humans, although several candidates are in various stages of development. These vaccines aim to prevent a range of staphylococcal infections, including skin and soft tissue infections, pneumonia, bloodstream infections, and toxic shock syndrome.

It's important to note that while antibiotics can be effective against staphylococcal infections, the bacteria have become increasingly resistant to these drugs over time, making vaccines an important area of research and development for preventing and controlling the spread of these infections.

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. It typically contains an agent that resembles the disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it encounters in the future.

Vaccines can be prophylactic (to prevent or ameliorate the effects of a future infection by a natural or "wild" pathogen), or therapeutic (to fight disease that is already present). The administration of vaccines is called vaccination. Vaccinations are generally administered through needle injections, but can also be administered by mouth or sprayed into the nose.

The term "vaccine" comes from Edward Jenner's 1796 use of cowpox to create immunity to smallpox. The first successful vaccine was developed in 1796 by Edward Jenner, who showed that milkmaids who had contracted cowpox did not get smallpox. He reasoned that exposure to cowpox protected against smallpox and tested his theory by injecting a boy with pus from a cowpox sore and then exposing him to smallpox, which the boy did not contract. The word "vaccine" is derived from Variolae vaccinae (smallpox of the cow), the term devised by Jenner to denote cowpox. He used it in 1798 during a conversation with a fellow physician and later in the title of his 1801 Inquiry.

Inactivated vaccines, also known as killed or non-live vaccines, are created by using a version of the virus or bacteria that has been grown in a laboratory and then killed or inactivated with chemicals, heat, or radiation. This process renders the organism unable to cause disease, but still capable of stimulating an immune response when introduced into the body.

Inactivated vaccines are generally considered safer than live attenuated vaccines since they cannot revert back to a virulent form and cause illness. However, they may require multiple doses or booster shots to maintain immunity because the immune response generated by inactivated vaccines is not as robust as that produced by live vaccines. Examples of inactivated vaccines include those for hepatitis A, rabies, and influenza (inactivated flu vaccine).

A viral vaccine is a biological preparation that introduces your body to a specific virus in a way that helps your immune system build up protection against the virus without causing the illness. Viral vaccines can be made from weakened or inactivated forms of the virus, or parts of the virus such as proteins or sugars. Once introduced to the body, the immune system recognizes the virus as foreign and produces an immune response, including the production of antibodies. These antibodies remain in the body and provide immunity against future infection with that specific virus.

Viral vaccines are important tools for preventing infectious diseases caused by viruses, such as influenza, measles, mumps, rubella, polio, hepatitis A and B, rabies, rotavirus, chickenpox, shingles, and some types of cancer. Vaccination programs have led to the control or elimination of many infectious diseases that were once common.

It's important to note that viral vaccines are not effective against bacterial infections, and separate vaccines must be developed for each type of virus. Additionally, because viruses can mutate over time, it is necessary to update some viral vaccines periodically to ensure continued protection.

Combined vaccines are defined in medical terms as vaccines that contain two or more antigens from different diseases, which are given to provide protection against multiple diseases at the same time. This approach reduces the number of injections required and simplifies the immunization schedule, especially during early childhood. Examples of combined vaccines include:

1. DTaP-Hib-IPV (e.g., Pentacel): A vaccine that combines diphtheria, tetanus, pertussis (whooping cough), Haemophilus influenzae type b (Hib) disease, and poliovirus components in one injection to protect against these five diseases.
2. MMRV (e.g., ProQuad): A vaccine that combines measles, mumps, rubella, and varicella (chickenpox) antigens in a single injection to provide immunity against all four diseases.
3. HepA-HepB (e.g., Twinrix): A vaccine that combines hepatitis A and hepatitis B antigens in one injection, providing protection against both types of hepatitis.
4. MenACWY-TT (e.g., MenQuadfi): A vaccine that combines four serogroups of meningococcal bacteria (A, C, W, Y) with tetanus toxoid as a carrier protein in one injection for the prevention of invasive meningococcal disease caused by these serogroups.
5. PCV13-PPSV23 (e.g., Vaxneuvance): A vaccine that combines 13 pneumococcal serotypes with PPSV23, providing protection against a broader range of pneumococcal diseases in adults aged 18 years and older.

Combined vaccines have been thoroughly tested for safety and efficacy to ensure they provide a strong immune response and an acceptable safety profile. They are essential tools in preventing various infectious diseases and improving overall public health.

I could not find a specific medical definition for "Vaccines, DNA." However, I can provide you with some information about DNA vaccines.

DNA vaccines are a type of vaccine that uses genetically engineered DNA to stimulate an immune response in the body. They work by introducing a small piece of DNA into the body that contains the genetic code for a specific antigen (a substance that triggers an immune response). The cells of the body then use this DNA to produce the antigen, which prompts the immune system to recognize and attack it.

DNA vaccines have several advantages over traditional vaccines. They are relatively easy to produce, can be stored at room temperature, and can be designed to protect against a wide range of diseases. Additionally, because they use DNA to stimulate an immune response, DNA vaccines do not require the growth and culture of viruses or bacteria, which can make them safer than traditional vaccines.

DNA vaccines are still in the experimental stages, and more research is needed to determine their safety and effectiveness. However, they have shown promise in animal studies and are being investigated as a potential tool for preventing a variety of infectious diseases, including influenza, HIV, and cancer.

Synthetic vaccines are artificially produced, designed to stimulate an immune response and provide protection against specific diseases. Unlike traditional vaccines that are derived from weakened or killed pathogens, synthetic vaccines are created using synthetic components, such as synthesized viral proteins, DNA, or RNA. These components mimic the disease-causing agent and trigger an immune response without causing the actual disease. The use of synthetic vaccines offers advantages in terms of safety, consistency, and scalability in production, making them valuable tools for preventing infectious diseases.

Bacterial vaccines are types of vaccines that are created using bacteria or parts of bacteria as the immunogen, which is the substance that triggers an immune response in the body. The purpose of a bacterial vaccine is to stimulate the immune system to develop protection against specific bacterial infections.

There are several types of bacterial vaccines, including:

1. Inactivated or killed whole-cell vaccines: These vaccines contain entire bacteria that have been killed or inactivated through various methods, such as heat or chemicals. The bacteria can no longer cause disease, but they still retain the ability to stimulate an immune response.
2. Subunit, protein, or polysaccharide vaccines: These vaccines use specific components of the bacterium, such as proteins or polysaccharides, that are known to trigger an immune response. By using only these components, the vaccine can avoid using the entire bacterium, which may reduce the risk of adverse reactions.
3. Live attenuated vaccines: These vaccines contain live bacteria that have been weakened or attenuated so that they cannot cause disease but still retain the ability to stimulate an immune response. This type of vaccine can provide long-lasting immunity, but it may not be suitable for people with weakened immune systems.

Bacterial vaccines are essential tools in preventing and controlling bacterial infections, reducing the burden of diseases such as tuberculosis, pneumococcal disease, meningococcal disease, and Haemophilus influenzae type b (Hib) disease. They work by exposing the immune system to a harmless form of the bacteria or its components, which triggers the production of antibodies and memory cells that can recognize and fight off future infections with that same bacterium.

It's important to note that while vaccines are generally safe and effective, they may cause mild side effects such as pain, redness, or swelling at the injection site, fever, or fatigue. Serious side effects are rare but can occur, so it's essential to consult with a healthcare provider before receiving any vaccine.

There have been[timeframe?] two RCTs with staphylococcal toxoid vaccine. A small RCT showed considerable benefit and a large ... Andersson M, Bagby JR, Dyrehag L, Gottfries C (1998). "Effects of staphylococcus toxoid vaccine on pain and fatigue in patients ...
Human use is mostly restricted to eastern Europe to treat chronic and recurrent diseases, for example chronic staphylococcal ... Autogenous vaccines, also called autologous vaccines, autovaccines, "self" or custom vaccines, are vaccines that are prepared ... including autogenous vaccines. Vaccine Therapeutic vaccines Immune system Immunotherapy Giedrys-Kalemba S, Czernomysy-Furowicz ... Autogenous vaccines have been researched since as early as the 1900s. This type of vaccine was first introduced by Sir Almroth ...
... to use in vaccines). Using this method, he developed vaccines for gonorrhea, some staphylococcal infections, and cholera. These ... He did not succeed in his effort to develop a practical vaccine. The next step would be taken by Rudolf Weigl in 1930. Despite ... He first tried this vaccine on himself, and when he stayed healthy he tried it on a few children (because of their better ... Nicolle surmised that he could make a simple vaccine by crushing up the lice and mixing it with blood serum from recovered ...
The vaccine, called Rotashield™ (Wyeth Lederle Vaccines and Pediatrics] was a live attenuated virus. Within months after ... county-wide surveillance system in Dallas County to include other severe infections by encapsulated bacteria and Staphylococcal ... Her seminal work on Hib vaccines elucidated the effects of introduction of new Hib vaccines on both bacterial carriage and ... There was controversy about the efficacy of this vaccine and, subsequently, it was replaced by second-generation Hib vaccines ...
2010). "Population impact of Vi capsular polysaccharide vaccine". Expert Review of Vaccines. 9 (5): 485-496. doi:10.1586/erv. ... Also produced were anti-plague, anti-typhoid, anti-staphylococcal, anti-gonococcal, anti-colibacillairy, anti-streptococcal and ... The Institute also kept a reserve of 1 000 000 cc of anti-cholera vaccine to be used in the event of a cholera epidemic. The ... He was responsible for the large scale production of vaccines for human use. The Dalat facility was taken over by the ...
Staphylococcal Investigational Vaccine in Healthy Adults" at ClinicalTrials.gov "Status of vaccine research and development of ... As of 2016, this vaccine is no longer under active development. Pfizer's S. aureus four-antigen vaccine SA4Ag was granted fast ... As of 2021, no approved vaccine exists against S. aureus. Early clinical trials have been conducted for several vaccines ... Vaccine. 35 (8): 1132-1139. doi:10.1016/j.vaccine.2017.01.024. PMID 28143674. Torre A, Bacconi M, Sammicheli C, Galletti B, ...
... typhoid-paratyphoid vaccines MeSH D20.215.894.135.720 - shigella vaccines MeSH D20.215.894.135.744 - staphylococcal vaccines ... hepatitis a vaccines MeSH D20.215.894.899.955.400 - hepatitis b vaccines MeSH D20.215.894.899.970 - yellow fever vaccine MeSH ... measles vaccine MeSH D20.215.894.899.404.500 - measles-mumps-rubella vaccine MeSH D20.215.894.899.488 - mumps vaccine MeSH ... rubella vaccine MeSH D20.215.894.899.779.500 - measles-mumps-rubella vaccine MeSH D20.215.894.899.790 - saids vaccines MeSH ...
T-cell populations can be tracked over the duration of a virus or after the application of a vaccine. Tetramer stains can also ... "Staphylococcal phosphatidylglycerol antigens activate human T cells via CD1a". Nature Immunology. 24 (1): 110-122. doi:10.1038/ ... This allowed for comparison of the immune response (the number of T-cells that target a virus) in two different vaccine ... Another study utilized MHC tetramer complexes to investigate the effectiveness of an influenza vaccine delivery method. Mice ...
"Vaccine Safety". Vaccine.gov. US National Vaccine Program Office. Archived from the original on March 13, 2019. Retrieved ... The virus can, however, transmit other diseases, including hepatitis B, group A streptococcal infection, and staphylococcal ... Before the chickenpox vaccine became available, 100 to 150 children in the U.S. died from chickenpox annually. In the UK, ... "History of Vaccine Safety". US CDC. Archived from the original on March 28, 2019. Retrieved March 23, 2019. "Surveillance for ...
Vaccine. 34 (51): 6582-96. doi:10.1016/j.vaccine.2016.09.025. PMID 27863715. Sharma C, Ganigara M, Galeotti C, Burns J, ... staphylococcal scalded skin syndrome, toxic epidermal necrolysis, and Lyme disease. In 2020, reports of a Kawasaki-like disease ... For study purposes, including vaccine safety monitoring, an international case definition has been proposed to categorize ' ... staphylococcal and streptococcal toxin-mediated diseases such as scarlet fever and toxic shock syndrome; drug hypersensitivity ...
He worked on a live vaccine against influenza, but the vaccine was unsuccessful when tested during World War II. His interest ... However, it turned out to be another toxin that had caused the children's deaths; this work on staphylococcal toxin piqued his ... Burnet focused the Institute in the search for a vaccine. He first tested the vaccine on a group of medical students, and after ... Modern methods for producing influenza vaccines are still based on Burnet's work improving virus growing processes in hen's ...
Song L, Hobaugh MR, Shustak C, Cheley S, Bayley H, Gouaux JE (December 1996). "Structure of staphylococcal alpha-hemolysin, a ... Bubeck Wardenburg J, Schneewind O (February 2008). "Vaccine protection against Staphylococcus aureus pneumonia". The Journal of ...
A staphylococcal-specific lysin that the Fischetti lab developed is currently in phase 3 human clinical trials and if ... The first, M6 Pharmaceuticals a David Blech company filed in 1994, developed mucosal anti-infective vaccines, but failed due to ... ContraFect developed a Staphylococcal lysin that successfully completed FDA phase 1 and phase 2 human clinical trials, the only ... This information is now critical for the development of anti-infectives and vaccines. Also, by searching the bacterial sequence ...
... recognized by HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes which could be used as cancer vaccines, and in fact ... and to directly assist in the refolding of Staphylococcal nuclease. Aside from these bacteria, PPIB has been identified in ...
There have been several attempts to create a vaccine in the past few decades. These vaccines, which are still in the ... Staphylococcal scalded skin syndrome: This is a disease that occurs primarily in young children due to a toxin-producing strain ... Although there are currently no vaccines available, the vaccine approach has a greater likelihood of effectively preventing ... A vaccine that will protect against the 180 to 200 types of bacteria causing the disease has been worked on for over 20 years, ...
In addition, staphylococcal isolates from the nasopharynges and hands of health care workers were shown to be genetically ... were killed and about 30 required medical attention after receiving vaccines for Hepatitis B, the Mexican Social Security ... S. hominis, as well as most other staphylococcal species common on the human skin, is able to produce acid aerobically from ... In a certain study, S. hominis was calculated to account for 22% of the total staphylococcal species recovered from individuals ...
GarcĂ­a, Maricarmen; Zavala, Guillermo (28 January 2019). "Commercial vaccines and vaccination strategies against infectious ... in chickens Ornithobacterium rhinotracheale Pullorum disease Riemerella anatipestifer Salmonellosis in poultry Staphylococcal ...
Immunization Principles and Vaccine Use Chapter 119: Health Recommendations for International Travel Chapter 120: Climate ... Staphylococcal Infections Chapter 143: Streptococcal Infections Chapter 144: Enterococcal Infections Chapter 145: Diphtheria ...
Conjugates are being developed as vaccines or are already being used without a priori knowledge. A peculiarity first recognized ... No association with occurrence of severe staphylococcal infection was found. Moreover, a recent study reported rs111200466, a ...
Anterior blepharitis is either staphylococcal blepharitis, or seborrhoeic blepharitis and posterior blepharitis is due to the ... Other drugs include:propranolol, valproic acid, barbiturates, MMR vaccine, botulinum toxin, epinephrine, antithyroid drugs, ... Anterior blepharitis is either staphylococcal blepharitis, or seborrhoeic blepharitis which have symptoms of the presence of ...
During WW II, Bernheimer contributed to the development of a vaccine against gas gangrene. Throughout his career, he was ... Schwartz, L. L. (1963). "Isolation and Composition of Staphylococcal Alpha Toxin". Journal of General Microbiology. 30 (3): 455 ...
A key element of the Act was to allow stockpiling and distribution of vaccines that had not been tested for safety or efficacy ... In 1964, research programs involved staphylococcal enterotoxins capable of causing food poisoning. Research initiatives also ... Some vaccines also have applicability for diseases of domestic animals (e.g., Rift Valley fever and Venezuelan equine ... The Project Bioshield Act was passed by Congress in 2004 calling for $5 billion for purchasing vaccines that would be used in ...
Toxins that can be used as weapons include ricin, staphylococcal enterotoxin B, botulinum toxin, saxitoxin, and many mycotoxins ... Hassani M, Patel MC, Pirofski LA (April 2004). "Vaccines for the prevention of diseases caused by potential bioweapons". ... Would demonstrate how to render a vaccine ineffective; Would confer resistance to therapeutically useful antibiotics or ... Staphylococcal enterotoxin B). The United States developed an anti-crop capability during the Cold War that used plant diseases ...
Antibody responses to vaccines are frequently poor. Loss of Dock8 protein expression can be demonstrated by diagnostic ... The disease is characterized by eczema, recurrent cold staphylococcal abscesses, recurrent lung infections, coarse facial ...
This procedure fell out of favor in the late 1950s, at a time when antibiotics and the polio vaccine were becoming widely used ... staphylococcal sepsis, peritonitis, botulism, poliomyelitis, non-healing wounds, and asthma. One of the best known and most ...
The oral cholera vaccine has been found to be 50-60% effective over two years. There are a number of vaccines against ... Lin, Z; Kotler, DP; Schlievert, PM; Sordillo, EM (May 2010). "Staphylococcal enterocolitis: forgotten but not gone?". Digestive ... Two commercial rotavirus vaccines exist and several more are in development. In Africa and Asia these vaccines reduced severe ... This vaccine may also prevent illness in non-vaccinated children by reducing the number of circulating infections. Since 2000, ...
This capability was used to detect new variants that alter vaccine efficacy, disease severity and/or transmissibility, and was ... Peacock, Sharon Jayne (2003). Staphylococcal fibronectin-binding proteins. open.ac.uk (PhD thesis). Open University. doi: ... vaccines, and methods of diagnosing, preventing and controlling diseases. In 2019, Peacock returned to the University of ... critically important for public health interventions and vaccine roll-out. Consortium members undertook research that revealed ...
In rare instances, bullous impetigo can spread and lead to Staphylococcal Scalded Skin Syndrome (SSSS), a potentially life- ... Expert Review of Vaccines. 16 (8): 833-843. doi:10.1080/14760584.2017.1343669. PMC 5739310. PMID 28644696. Esposito S, Principi ... Brazel M, Desai A, Are A, Motaparthi K (October 2021). "Staphylococcal Scalded Skin Syndrome and Bullous Impetigo". Medicina. ... Dollani LC, Marathe KS (April 2020). "Impetigo/Staphylococcal Scalded Skin Disease". Pediatrics in Review. 41 (4): 210-212. doi ...
In addition, Staphylococcal Enterotoxin B was produced as an incapacitating agent. During summer 1972, Nixon nominated General ... These shortcomings included inadequate training, a lack of decontamination kits and other equipment, and vaccine shortages. ...
Since there is no commercial vaccine available yet, the vaccine used is an autogenous vaccine with the strain of S. hyicus that ... Further, it has been suggested that resistance may be passed between staphylococcal species especially when treating pigs ... A vaccine can be used for prevention of infection with S. hyicus. The vaccine is made using the genes that encode exfoliative ... doi:10.1111/j.1439-0450.1979.tb00814.x. Nishifuji K, Sugai M, Amagai M (January 2008). "Staphylococcal exfoliative toxins: " ...
Smallpox Vaccines: From Live Vaccinia Virus to Subunits *. A cell culture-derived smallpox vaccine, ACAM2000®, was recently ... Additional vaccine approaches (e.g., subunit vaccines) are also under development, but their evaluation is in relatively early ... Animal Models for Testing Smallpox Vaccines *. Since there is no clinical smallpox and human challenge with variola virus would ... Molecular markers of vaccine immune protection are being determined, as this would be critical for efficacy assessment. Since ...
Vaccines. Class Summary. Active immunization increases resistance to infection. Vaccines consist of microorganisms or cellular ... Useful for treatment against streptococcal and most staphylococcal infections. Gentamicin (Garamycin). *View full drug ... Seasonal flu vaccine and H1N1 vaccine are recommended, especially for those who have undergone Fontan operation. ... In patients with impaired splenic function, immunization with Haemophilus influenzae vaccine, pneumococcal vaccine, and ...
Categories: Staphylococcal Vaccines Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, ...
... agents and vaccines; (ii) host responses to anti-staphylococcal agents and/or vaccines; (iii) epidemiological studies to ... immune responses to vaccines. Investigations in these four major research areas include Phase I/II clinical trials, clinical ... staphylococcal colonization and infections, including methicillin-resistant staphylococcus aureus; (iii) susceptibility to ...
... a conjugate vaccine can confer partial immunity against S. aureus bacteremia for approximately 40 weeks, after which protection ... Staphylococcal Vaccines* Actions. * Search in PubMed * Search in MeSH * Add to Search ... Fattom AI, Horwith G, Fuller S, Propst M, Naso R. Fattom AI, et al. Vaccine. 2004 Feb 17;22(7):880-7. doi: 10.1016/j.vaccine. ... Vaccines for healthcare associated infections without vaccine prevention to date. Amandine GB, Gagnaire J, Pelissier C, ...
... the introduction of live vaccine into the environment and the clinical and epidemiologic need to differentiate vaccine strains ... Outbreaks of salmonellosis, shigellosis, staphylococcal food poisoning, pathogenic Escherichia coli, typhoid fever, and ... Because development of an influenza virus vaccine had been a high priority of the U.S. military during World War II to avert ... Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005;59:587--635. ...
Vancomycin-Resistant Staphylococcus aureus see Antibiotic Resistance; Staphylococcal Infections * Varicella-Zoster Virus see ... Vaccines * Vaginal Yeast Infection see Yeast Infections * Valley Fever * Vancomycin-Resistant Enterococci see Antibiotic ...
A vaccine to prevent postoperative S aureus infection is associated with an overall lack of efficacy and a higher mortality ... Diseases & Conditions Staphylococcal Meningitis * 2002161328-overview. Diseases & Conditions Saphenous Vein Graft Aneurysms ... The vaccine is based on the 0657nI iron surface determinant B.. The primary endpoint was bacteremia and/or deep sternal wound ... A candidate vaccine from Merck, V710, appears safe and evoked an antibody response in healthy volunteers but is neither ...
Challenges for a universal Staphylococcus aureus vaccine. Clin Infect Dis. 2012 Apr. 54 (8):1179-86. [QxMD MEDLINE Link]. ... encoded search term (Staphylococcal Meningitis) and Staphylococcal Meningitis What to Read Next on Medscape ... Staphylococcal Meningitis. Updated: Jun 19, 2018 * Author: Lawrence A Zumo, MD; Chief Editor: Niranjan N Singh, MBBS, MD, DM, ... In a recent case series, out of 62 patients, 37 cases were due to Staphylococcal aureus and 25 cases due to coagulase-negative ...
There have been[timeframe?] two RCTs with staphylococcal toxoid vaccine. A small RCT showed considerable benefit and a large ... Andersson M, Bagby JR, Dyrehag L, Gottfries C (1998). "Effects of staphylococcus toxoid vaccine on pain and fatigue in patients ...
Serologic studies of staphylococcal enterotoxin Cite CITE. Title : Serologic studies of staphylococcal enterotoxin Personal ... Live attenuated poliomyelitis vaccine Cite CITE. Title : Live attenuated poliomyelitis vaccine Personal Author(s) : Burney, ... Community spread of orally administered attenuated poliovirus vaccine strains Cite CITE. Title : Community spread of orally ... Title : Poliomyelitis in Idaho after use of live virus vaccine Personal Author(s) : Eklund, Carl M.;Bell, E. John;Gerloff, ...
Erythromycin is used for treatment of staphylococcal and streptococcal infections. In children, age, weight, and severity of ... Vaccines. Class Summary. In June, 2016, the first U.S. cholera vaccine was approved by the FDA. [20] ... The cholera vaccine Vaxchora is the only one approved by the FDA for cholera prevention. It is a live, weakened vaccine ... Sack D, Cadoz M. Cholera vaccines. Plotkin SA, Orenstein WA. Vaccines. Philadelphia: WB Saunders Company; 1999. 639-649. ...
Urushibata Y, Itoh K, Ohshima M, Seto Y. Urushibata Y, et al. Clin Vaccine Immunol. 2010 Nov;17(11):1708-17. doi: 10.1128/CVI. ... Generation of Fab fragment-like molecular recognition proteins against staphylococcal enterotoxin B by phage display technology ... Epub 2010 Sep 15. Clin Vaccine Immunol. 2010. PMID: 20844088 Free PMC article. ...
Staphylococcal Vaccines Preferred Concept UI. M0020429. Registry Number. 0. Terms. Staphylococcal Vaccines Preferred Term Term ... Vaccines [D20.215.894] * Bacterial Vaccines [D20.215.894.135] * Anthrax Vaccines [D20.215.894.135.063] ... Staphylococcal Vaccines. Tree Number(s). D20.215.894.135.744. Unique ID. D013209. RDF Unique Identifier. http://id.nlm.nih.gov/ ... STAPH VACCINES. Registry Number. 0. NLM Classification #. WC 250. Public MeSH Note. 65. History Note. 65. Date Established. ...
Staphylococcal Vaccines Preferred Concept UI. M0020429. Registry Number. 0. Terms. Staphylococcal Vaccines Preferred Term Term ... Vaccines [D20.215.894] * Bacterial Vaccines [D20.215.894.135] * Anthrax Vaccines [D20.215.894.135.063] ... Staphylococcal Vaccines. Tree Number(s). D20.215.894.135.744. Unique ID. D013209. RDF Unique Identifier. http://id.nlm.nih.gov/ ... STAPH VACCINES. Registry Number. 0. NLM Classification #. WC 250. Public MeSH Note. 65. History Note. 65. Date Established. ...
Therefore, the development of an effective vaccine against ZIKV became an urgent need. Live attenuated vaccines present some ... The vaccines average population coverage is estimated to be 87.86%, which indicates it can be administered worldwide. ... In conclusion, we developed an in silico universal vaccine predicted to induce broad and high-coverage cellular and humoral ... ZIKV Envelope protein domain III (EDIII) was added to the vaccine construct, creating a hybrid protein domain-multiepitope ...
Tests of Salmonella Sub-unit Proteins as Vaccines for Broiler Chickens FREIE UNIVERSITAT BERLIN * Influence of Vaccines, Host ... Genomic Analysis of Staphylococcal Diversity and Antimicrobial Resistance (resistome) in Retail Poultry Products ... Vaccines to Reduce Salmonella Infantis in Chickens FOUNDATION FOR MEAT AND POULTRY RESEARCH AND, WASHINGTON, DC * ... Influence of Vaccines, Host Genetics and Pathogen Mutation Rates on the Evolutionary Dynamics of Infectious Diseases - Purdue ...
It can be used as a sole agent, or mixed into injection or sublingual immunotherapy vaccines. ... Methicillin resistance in the staphylococcal bacterium is mediated by the acquisition of a mobile gene cassette (staphylococcal ... Staphylococcal infections in dogs are not as simple to treat since the emergence of methicillin resistance. Most infections in ... Once methicillin resistant staphylococcal infections are diagnosed, there is a 50% chance that subsequent infections will be ...
Infectious Disease > COVID-19 Vaccine MIS-C After COVID Vaccination Exceedingly Rare in Young People. - Most cases involved ... One co-author disclosed a patent for staphylococcal antibody. One co-author disclosed being president of the Pediatric ... MIS-C is listed as a potential adverse event of special interest for COVID vaccine safety monitoring, due to "its known ... In addition, some cases of MIS-C acquired prior to full vaccination "will appear to be temporally associated with the vaccine" ...
Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant. Yang, Y., Back, C., Gräwert, M., Wahid, A ...
... staphylococcal enterotoxins and shellfish poisons. His presentation will focus on the biological characteristics and mechanism ... Vaccines Publication Types: Lecture. Webcast NLM Classification: QW 630.5.R5 NLM ID: 101285715 ... staphylococcal enterotoxins and shellfish poisons. His presentation will focus on the biological characteristics and mechanism ...
Staphylococcal_Enterotoxin_B,modify,26-JAN-07,(null),(null) C2650,Synchrotope_TA2M_Plasmid_DNA_Vaccine,modify,26-JAN-07,(null ... Vaccine,modify,26-JAN-07,(null),(null) C2628,MUC-2-Globo_H-KLH_Conjugate_Vaccine,modify,26-JAN-07,(null),(null) C2465,MUC-2-KLH ... Vaccine,modify,26-JAN-07,(null),(null) C2415,Potassium_Oxonate,modify,26-JAN-07,(null),(null) C2497,PSA_Prostate_Cancer_Vaccine ... Vaccine,modify,26-JAN-07,(null),(null) C26449,Monoclonal_Antibody_ACA125_Anti-Idiotype_Vaccine,modify,26-JAN-07,(null),(null) ...
Because the most widely used vaccines are administered during the first year of life and the antecedents of allergic disease ... Primary study outcomes are the development of protective immunity to common childhood vaccines (i.e. rotavirus, Haemophilus ... may affect vaccine immunogenicity in populations among whom these infections are endemic. Further, the low prevalence of ... on the development of vaccine immunity and allergy. The data will inform an ongoing debate of potential effects of geohelminths ...
This includes the flu vaccine and COVID-19 vaccine for everyone age 6 months and up. This critically important step puts the ... All staphylococcal infections. This includes Methicillin-resistant Staphylococcus aureus (MRSA) carriers or children with ... Note: the child may be excluded if they have not completed the recommended vaccine series until it is clear that they do not ...
... tick-borne encephalitis virus and vaccine antigens, or polyclonal stimuli including Staphylococcal enterotoxin and ...
  • These are increasingly severe staphylococcal skin infections. (medscape.com)
  • 2 It commonly follows superficial Staphylococcal infections of the umbilical, pectoral and perineal areas and may follow procedures like circumcision. (ispub.com)
  • Based on 40+ years of research, ImmLab has developed novel technological inventions for the prevention and treatment of staphylococcal infections in humans and animals. (immlab.com)
  • ImmLab's product line of staphylococcal-lysate-based vaccines for prevention and treatment of staphylococcal infections in humans, companion animals, and farm animals not only improves the health and well-being of those subject to microbial infections but does so using an approach that will not add to the growing threat of antibiotic-resistant bacterial strains and super-pathogens. (immlab.com)
  • Vaccines are available as aids to prevent abortion due to EHV-1 infections. (ontario.ca)
  • Prosthetic Knee Infection by a-hemolytic Streptococcus Species Prosthetic joint infections are most commonly caused by staphylococcal species, but this case of a prosthetic knee infection demonstrates the potential of a-hemolytic Streptococcus infection as well. (medscape.com)
  • Should First-line Empiric Treatment Strategies for Neonates Cover Coagulase-negative Staphylococcal Infections in Kenya? (kemri-wellcome.org)
  • We are excited about the potential impact this vaccine could have in preventing S. aureus infections, which have long posed significant challenges to global health and where antibiotic resistance is developing fast," said Birgitte Rønø, Chief Scientific Officer at Evaxion. (evaxion-biotech.com)
  • If the mice had staph infections prior to vaccination, we believe the vaccine candidates may not work. (scienceinter.com)
  • A vaccine to prevent postoperative infection with Staphylococcus aureus in patients undergoing cardiothoracic surgery is associated with an overall lack of efficacy and a higher mortality rate among patients who become infected, according to a study published in the April 3 issue of JAMA . (medscape.com)
  • Our aim was to provide information about the production of Egg White Immunoglobulin (EWIg) with specificity to Staphylococcal protein-A , a surface antigen of Staphylococcus aureus and to study the inhibition of this bacterium growth in pre- and post-immunized hens. (omicsonline.org)
  • In the ongoing search for a vaccine to battle the aggressive methicillin-resistant staphylococcus aureus, a University of Southern Mississippi biological science professor and student have developed an online database that holds collected data on genes related to staph. (technologynetworks.com)
  • The poster entitled "EVX-B1: An AI-designed vaccine against Staphylococcus aureus , demonstrating full disease protection and complete bacterial clearance" is presented at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA, taking place from 30th of July to 4 t h of August this year ( https://www.grc.org/staphylococcal-diseases-conference/2023/ ). (evaxion-biotech.com)
  • Researchers believe they have discovered why multiple human clinical trials of staphylococcus vaccines have failed: the bacteria knows too much about us. (scienceinter.com)
  • You may not die immediately, but you will die because they have weaponized synthetically recreated crate venom, cobra venom, HIV glycoprotein 120, and what's called staphylococcal Enterotoxin D, which is a very aggressive gram-positive bacteria," she warned. (naturalnews.com)
  • Establishment of a new animal model of allergic rhinitis with biphasic sneezing by intranasal sensitization with Staphylococcal enterotoxin B. Exp Ther Med. (southernbiotech.com)
  • Staphylococcal TSS is a potentially life-threatening systemic bacterial intoxication. (medscape.com)
  • Primary direct effect: vaccines against bacterial diseases reduce the incidence of the disease and consequently the use of antibiotics. (unime.it)
  • The IsdB vaccine worked in mice that had never been exposed to normal staph, generating antibodies that targeted the entire protein and disrupted bacterial functions. (scienceinter.com)
  • However, in mice that had previously been exposed to staph, the vaccine only produced antibodies against the unprotected portion of the IsdB protein, leaving bacterial function unaffected. (scienceinter.com)
  • This retrospective analysis of reported cases of meningitis in Bahrain aimed to assess the trend in the incidence of bacterial meningitis from 1990 to 2013, before and after the introduction of new vaccines. (who.int)
  • The changing trend in the etiology of bacterial meningitis points to the need to study vaccination programme modifications, such as pneumococcal vaccine for the adult population, especially high-risk groups. (who.int)
  • However, the epidemiol- the introduction of new vaccines and concerned with treatment of such cases ogy of bacterial meningitis continues the change in the incidence of bacterial in the country. (who.int)
  • The vaccine elicited antibodies but was not significantly more effective in preventing infection than placebo (22/3528 for recipients included in the analysis vs 27/3517 for control patients) at any time during the trial. (medscape.com)
  • The vaccine elicitation of HIV-neutralizing antibodies with tier-2-neutralization breadth has been a challenge. (bvsalud.org)
  • In addition, our group has also used our panel of well characterized monoclonal antibodies against S. mutans P1, a recognized target of protective immunity and widely studied candidate vaccine antigen, to demonstrate that exogenously administered antibodies included as part of an immune complex prior to immunization can be used in a directed and practical manner to alter the host antibody response against the bacteria towards one of increased efficacy. (ufl.edu)
  • When researchers mixed human IsdB antibodies with vaccine-derived protective antibodies, the latter stopped working. (scienceinter.com)
  • COPENHAGEN, Denmark, July 31, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA. (evaxion-biotech.com)
  • 7-Year-Old Girl Oozes Blood from Eye After Receiving Pfizer COVID-19 Vaccine in Thailand. (healthimpactnews.com)
  • A case study was published earlier this month in the Journal Français d'Ophtalmologie reporting an anterior uveitis case that developed after the first dose of COVID-19 vaccine in a 54-year-old female. (healthimpactnews.com)
  • That's an average of 992 cases of eye disorders reported each month following COVID-19 vaccine injections, and this is most certainly NOT an exhaustive list of eye disorders. (healthimpactnews.com)
  • Safety Monitoring of Novavax COVID-19 Vaccine in Those >12 Years This CDC report confirms the safety of the Novavax COVID-19 vaccine in adolescents and adults 12 years of age and older. (medscape.com)
  • Among all cases of S aureus infection, the 5 deaths attributed to multiorgan failure were all in vaccine recipients. (medscape.com)
  • The researchers cite other vaccines that seemed to have made matters worse (influenza, respiratory syncytial virus, and dengue) and hypothesize that humoral immunity may be insufficient to prevent S aureus infection postoperatively. (medscape.com)
  • Varicella vaccine seems to be effective in modifying the symptoms of varicella, but not potent enough in protecting from VZV infection. (vaccineriskawareness.com)
  • The primary niche for S. aureus in humans is the nares, and nasal carriage is a documented risk factor for staphylococcal infection. (unipv.it)
  • The mouse immunization studies demonstrate that ClfB is an attractive component for inclusion in a vaccine to reduce S. aureus nasal colonization in humans, which in turn may diminish the risk of staphylococcal infection. (unipv.it)
  • The search and study of genes related to staph is more imperative than ever to find a vaccine that can impact the new strains of staph. (technologynetworks.com)
  • The coagglutination test, which uses staphylococcal protein A, for serotyping strains of Streptococcus pneumoniae, was extended to include serotyping within serogroups. (bmj.com)
  • Fifty one strains of S pneumoniae, which belonged to one of the seven serogroups included in the 14 valent vaccine formulation, were tested, and no inconsistency was found when compared with the capsule swelling reaction. (bmj.com)
  • The characteristics of poliovirus strains circulating in Ukraine in 1982-1994″ (Mikrobiol[ogie] Z. vol. 60, no. 2, March-April 1998, pp. 44-49 [article in Russian]): "The long-term use of the live poliomyelitis vaccine has not stopped circulation of virulent polioviruses. (vaccineriskawareness.com)
  • However, these effects may be limited by the presence of microbial strains not included in vaccines or by their gene variation. (unime.it)
  • The AI technology has enabled the identification of novel S. aureus antigens, paving the way for the development of a vaccine with potential for broad protection against clinically relevant strains. (evaxion-biotech.com)
  • In the United States before rotavirus vaccines became available, a wave of rotavirus illness would begin in the Southwest in December and end in the Northeast in April or May. (msdmanuals.com)
  • A 54-year-old female patient, who did not have any disease other than diabetes mellitus, had complaints of redness, blurred vision, eye and headache that started in both eyes 3 days after the first dose of BNT162b2 mRNA (Pfizer-BioNTech) vaccine. (healthimpactnews.com)
  • We have previously reported on a case of a 7-year-old girl in Thailand who began oozing blood from her eyes and skin after receiving the Pfizer mRNA vaccine. (healthimpactnews.com)
  • According to the Multidisciplinary Digital Publishing Institute MDPI , there have been recent reports of hemorrhage, blood clots, and thrombocytopenia following the administration of mRNA COVID-19 vaccines that have raised concerns over the safety of genetic vaccines for people with pre-existing coagulation disorders or those on certain medications. (healthimpactnews.com)
  • With the dangerous COVID-19 mRNA shots now being extended to babies and toddlers, I decided to search the Government VAERS ( Vaccine Adverse Reporting System ) database for cases filed for various eye disorders. (healthimpactnews.com)
  • Studies on capsular serotyping of isolates are important for the rational design of mastitis vaccines, containing staphylococcal capsular antigens. (lupinepublishers.com)
  • Our proprietary EDEN platform rapidly identifies novel, highly protective antigens for the use in pathogen-specific prophylactic vaccines against bacteria. (evaxion-biotech.com)
  • Dennis undertook pioneering research on expression of virulence factors in the mammary gland during staphylococcal mastitis in sheep and cattle, and developed a vaccine adjuvant to target host defence mechanisms against these antigens leading to the patenting of a vaccine to control staphylococcal mastitis. (csiropedia.csiro.au)
  • Karen Kingston, a former Pfizer employee and current analyst who confirmed that the ingredients in the Wuhan coronavirus (COVID-19) vaccines are poison, revealed Pfizer-BioNTech's mission statement to strengthen the immune system to attack humans . (naturalnews.com)
  • Exemption breeds familiarity: Why don't staph vaccines work in humans? (scienceinter.com)
  • Staph vaccines appear to be so simple to make in laboratory mice because they rarely see S. aureus, but humans are exposed to staph beginning in the first weeks of life, and staph appears to have developed many strategies to render our immune response against them ineffective," Tsai explained. (scienceinter.com)
  • To test their hypothesis, Liu, Tsai, and co-authors replicated one of the largest failed staph vaccine trials in humans by targeting the IsdB protein, which S. aureus uses to acquire needed iron for functioning. (scienceinter.com)
  • The promising results showed the TSST-1 vaccine is safe and effective, with immunization lasting for at least two years. (noticiadesalud.com)
  • At the age of 18 days, the rabbits were subcutaneously injected with 1 milliliter of the Bordetella vaccine, followed by a week of booster immunization and 2 milliliters subcutaneously. (inxfhmh.cn)
  • Consider additional factors that will affect TB screening tests - TST and IGRA should not be completed within 4 weeks of live viral vaccines (which may have been given pre-departure - see below). (rch.org.au)
  • If improved vaccines against bovine mastitis are to be generated, more studies are required to elucidate the role of these polysaccharides in the pathogenesis of bovine mastitis [7]. (lupinepublishers.com)
  • This data would help in formulating vaccine based strategies for control of mastitis. (lupinepublishers.com)
  • Other bacteria frequently identified from aborted feti include Leptospira, Nocardia, Klebsiella and Staphylococcal species. (ontario.ca)
  • Vaccines contain either noninfectious components of bacteria or viruses or whole forms of these organisms that have been weakened. (msdmanuals.com)
  • Reduction of antibiotic resistance of vaccine target bacteria. (unime.it)
  • With the many previous unsuccessful attempts to develop an effective S. aureus vaccine, EVX-B1 instills renewed hope in the battle against the bacteria," said Steven Projan, PhD, Scientific Advisor to Evaxion and poster presenter. (evaxion-biotech.com)
  • As researchers work to find a vaccine for MRSA, Elasri said this program can cut a significant amount of time it takes to find information about staphylococcal genes. (technologynetworks.com)
  • Prevention, early recognition, and treatment of MRSA and TSS are crucial to prevent severe complications and improve outcomes," said Dr. Andreas Roetzer, Head of R&D for vaccines at Biomedical Research & Bio-Products AG. (noticiadesalud.com)
  • Examples of such vaccine interventions currently licensed include Hib and Pneumococcal conjugate vaccines while future vaccines under development in this category include Group B Streptococcal and Staphylococcal vaccines. (unime.it)
  • As targets for vaccine development and antimicrobial intervention are assessed, rodent nasal colonization models may be invaluable. (unipv.it)
  • We enrolled US Army Infantry trainees (Fort Benning, GA) in a phase 2, randomized, double-blind, placebo-controlled trial of NDV-3A, a vaccine containing a recombinant adhesin/invasion protein of Candida albicans that has structural similarity to the S. aureus protein clumping factor A. Study participants received one intramuscular dose of NDV-3A or placebo (adjuvant alone) within 72 h of arrival on base. (nih.gov)
  • Likewise, mice that were immunized systemically or intranasally with a recombinant vaccine composed of domain A of ClfB exhibited lower levels of colonization than control animals exhibited. (unipv.it)
  • Disease prevention strategies are needed, but a S. aureus vaccine does not currently exist. (nih.gov)
  • The categories of species pangenome such as core, accessory, and unique genes sets can be analyzed for the identification of vaccine candidates through reverse vaccinology. (biomedcentral.com)
  • The proposed pipeline has proved to be the first comprehensive automated pipeline that can precisely identify putative vaccine candidates exploiting the microbial pangenome. (biomedcentral.com)
  • A significant decrease in time and cost is observed using this strategy instead of culturing the whole microorganism to identify potential vaccine candidates (PVCs) [ 9 ]. (biomedcentral.com)
  • However, in all subsequent human trials, these vaccine candidates failed. (scienceinter.com)
  • Diseases are disappearing as a result of vaccines. (vaccineriskawareness.com)
  • 2. Secondary direct effect: vaccines can limit the use of antibiotics for secondary diseases by reducing the incidence of the primary disease. (unime.it)
  • The use of vaccines is essential not only in children and the elderly, but also in subjects with particular morbid conditions such as cardiovascular, respiratory, metabolic diseases, primary and / or secondary immunosuppression, etc., which expose them to an increased risk of contracting invasive infectious diseases and developing serious complications in this case. (unime.it)
  • It's a longstanding and enigma in the staphylococcal field," said George Liu, MD, PhD, professor of pediatrics at the University of California San Diego School of Medicine and chief of the Division of Infectious Diseases at Rady Children's Hospital-San Diego. (scienceinter.com)
  • Amid the novel coronavirus pandemic and beyond, the ImmLab human vaccine can be used in a protective anti-staphylococcal manner while also delivering significant benefits of specific and non-specific immunity boost needed for vulnerable populations. (immlab.com)
  • The incidence of meningitis due to H. influenzae and N. meningitidis showed a marked reduction after the introduction of the corresponding vaccines in 1998 and 2001 respectively, and S. pneumoniae became the predominant organism after Mycobacterium tuberculosis . (who.int)
  • Kingston further revealed that people are being injected with different versions of the vaccines: Some have weaponized spike protein in it, and some don't. (naturalnews.com)
  • Here, we report the isolation and characteristics of a CD4-binding site specific monoclonal antibody, HmAb64, from a human volunteer immunized with a polyvalent gp120 DNA prime-protein boost vaccine. (bvsalud.org)
  • ImmLab staphylococcal vaccines are created by introducing the genome of the staphylococcal bacteriophage into the staphylococcal cell, resulting in the production of highly immunogenic vaccine comprised of all staphylococcal proteins and cell-wall components. (immlab.com)
  • One of the main arguments that the medical profession use to get parents to consent to vaccination is the fear that the child might DIE of a vaccine-preventable disease, and they say that vaccination is to prevent deaths, save lives etc. (vaccineriskawareness.com)
  • In the first phase, the vaccines as per the WHO list were administered at the vaccination center belonging to the UOSD of Hospital Hygiene to which patients, healthcare workers and students of the health care area belonging to the university polyclinic are addressed. (unime.it)
  • A candidate vaccine from Merck, V710, appears safe and evoked an antibody response in healthy volunteers but is neither efficacious nor safe in surgical patients who become infected. (medscape.com)
  • A gp120 subunit-based vaccine can thus elicit an antibody capable of tier 2-HIV neutralization. (bvsalud.org)
  • These findings do not support the use of the V710 vaccine for patients undergoing surgical interventions," the researchers concur. (medscape.com)
  • This report reviews ACIP recommendations for RSV vaccine in adults over 60. (medscape.com)
  • Only one question- naire survey of community pharmacy one occasion when an individuals genetic predisposition pain denotes a longitudinal study involves single doses from the early rehabilitation gupta v, lipsitz la (2002) persistent nonmalignant pain and increased risk of delirium: A systematic approach targeted at making peptide administered in the 2005 pandemic h1n1 vaccine, j allergy clin immunol 106(4):553, 1997. (stonecottagegardens.com)
  • But allegedly if the laws have applied, the vials of the vaccine with the gray cap and the NDC [National Drug Code] codes that were issued on December 22, 2021, are lethal injections. (naturalnews.com)
  • Identification of the Negri bodies in the brain of an 8-year-old boy who died 8 days after a paralytic illness and 20 days after a dog bite, and who had received 9 injections of Semple's anti-rabies vaccine, provided evidence that he died of acute rabies encephalitis and not of post-vaccinal allergic encephalomyelitis. (vaccineriskawareness.com)
  • The first vaccine to potentially prevent Staphylococcal-induced Toxic Shock Syndrome (TSS) has successfully completed a Phase 2 study. (noticiadesalud.com)
  • The investigators randomly assigned 4015 patients to receive the vaccine within 14 to 60 days of cardiothoracic surgery and 4016 to receive a placebo. (medscape.com)
  • Like in gambling, recipients of the vaccine will have no choice but to accept what happens to them. (naturalnews.com)
  • Stratifying participants by those who became infected revealed a possible exacerbating association to the vaccine, although the researchers caution that this is not causal evidence. (medscape.com)
  • At the same time, the last 25 years have been marked by the increasing development, in the pharmaceutical field, of increasingly effective vaccines, such as those directed against pneumococci, Haemophilus influenzae type b (Hib), Rotavirus and, recently, ACWY meningococcus and B, as well as the most innovative flu vaccines. (unime.it)
  • Scientists have been looking for an effective vaccine for over a century, with at least 15 successful preclinical studies using animal models in the last 30 years. (scienceinter.com)
  • Vaccines are the most effective way to reduce that health burden and antibiotic resistance," Liu said, citing successes with childhood immunizations and the more recent COVID-19 vaccines as examples. (scienceinter.com)
  • Vance G. Fowler Jr, MD, MHS, from Duke University Medical Center, Durham, North Carolina, and colleagues conducted a multicenter, 4-year, primary modified intention-to-treat randomized phase 2b/3 clinical trial evaluating a single intramuscular injection of vaccine. (medscape.com)
  • Cite this: S aureus Vaccine for Heart Surgery Appears Harmful - Medscape - Apr 02, 2013. (medscape.com)
  • Previous studies with rodent models of nasal colonization have implicated capsule and teichoic acid as staphylococcal surface factors that promote colonization. (unipv.it)
  • Use of Respiratory Syncytial Virus Vaccines in Older Adults While RSV is usually associated with young children, it can also cause severe respiratory illness in older adults. (medscape.com)
  • And so that would explain why we're having such rash differentiations between reactions to the vaccine . (naturalnews.com)
  • Liu hypothesized, along with first author Chih-Ming Tsai, PhD, a project scientist in his lab, and others, that while laboratory mice with no previous exposure to S. aureus respond well to potential vaccines because they are completely novel, human versions do not because S. aureus has evolved defenses to fend off the therapeutic attack. (scienceinter.com)
  • Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy. (southernbiotech.com)
  • No parent would accept a vaccine for an illness they thought their child would easily recover from. (vaccineriskawareness.com)
  • The ever-increasing genomic and proteomic data has greatly facilitated the vaccine designing and development process. (biomedcentral.com)
  • The EVX-B1 vaccine candidate is ready for non-clinical development, CMC, and subsequent clinical testing. (evaxion-biotech.com)
  • Schistosoma mansoni tetraspanning orphan receptor (SmTOR): a new vaccine candidate against schistosomiasis. (southernbiotech.com)
  • If you notice, when the vaccine was introduced in the 1920's, the disease and death rates spiked on the graph, before reducing again, suggesting a relation to the vaccine. (vaccineriskawareness.com)
  • With highly encouraging data from the Phase 2 study building on a successful Phase 1, we believe the TSST-1 vaccine could represent a real breakthrough in protecting these groups, as well as medical workers in at-risk settings. (noticiadesalud.com)
  • EVX-B1 has been designed using Evaxion's proprietary AI technology for vaccine target discovery. (evaxion-biotech.com)
  • A successful preventative vaccine could also be used to protect medical staff. (noticiadesalud.com)
  • But it does give us a sub-set of data to compare to all other FDA-approved vaccines for the previous 30 years (360 months) prior to the roll out of the COVID-19 vaccines. (healthimpactnews.com)
  • The vaccine is based on the 0657nI iron surface determinant B. (medscape.com)